acquired by Cubist Pharmaceuticals in 1997, which following U.S. Food and Drug Administration (FDA) approval in September 2003, for use in people older than 18 years, began marketing the drug under the trade name Cubicin. Cubicin is marketed in the EU and in several other countries by Novartis following its purchase of Chiron Corporation, the previous licensee. References Further reading External links Antibiotics Cyclic peptides Depsipeptides Eli Lilly and Company brands AstraZeneca brands Lipopeptides Merck & Co. brands Peripheral membrane proteins Polypeptide antibiotics